DDInter396 DDInter636
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Clevidipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nitrendipine
Nitrendipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Apalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Calcium Channel Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Clevidipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nitrendipine (Compound) and Nitrendipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Clevidipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class) and Calcium Channel Antagonists (Pharmacologic Class) includes Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin